InSilicoTrials has entered a collaborative partnership with Axoltis Pharma to advance therapeutic solutions for neurological disorders.
The firms will develop disease-modifying drugs to treat patients with neurodegenerative and traumatic neurologic impairments.
The partnership aims to enhance the clinical development plan of Axoltis' drug candidate, NX210c, a 12-amino acid peptide derived from SCO-spondin.
This collaboration's key focus will be to use InSilicoTrials' platform and leverage its InSilicoNEURO suite, which consists of diverse mechanistic central nervous system (CNS) models.
Models within InSilicoNEURO will be used to evaluate the potential of Axoltis' drug candidate on virtual patients with conditions, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis.
Mechanistic CNS models simulate the physiological and pathological aspects of CNS disorders, offering a better understanding of disease mechanisms and possible therapeutic interventions.
Axoltis CEO Yann Godfrin stated: “Integrating their industry-leading AI and computational modelling solutions in the development plan of our promising disease-modifying drug will allow us to address the pressing challenges faced by individuals suffering from neurological disorders.”
The companies will leverage InSilicoTrials' digital platform and use data from Phase Ib clinical trials and the preclinical package to analyse the connection between NX210c dosing regimens, blood-brain barrier repair, neurological function, biomarker concentrations, clinical efficacy and safety outcomes.
This analysis will be achieved through computational modelling and simulation, and artificial intelligence techniques.
InSilicoTrials CEO Luca Emili stated: “Together, we aim to unlock new insights and develop groundbreaking treatments that will positively impact the lives of patients with neurologic impairments worldwide.”
